Figure 1 | Scientific Reports

Figure 1

From: Predicting treatment outcomes of intravitreal brolucizumab for polypoidal choroidal vasculopathy through noninvasive assessment of polypoidal lesion blood flow with optical coherence tomography angiography

Figure 1

Changes of average best-corrected visual acuity in eyes with polypoidal choroidal vasculopathy treated with 3 monthly intravitreal injections of brolucizumab followed by a treat-and-extend regimen with intravitreal brolucizumab. Best-corrected visual acuity (BCVA) significantly improved throughout the 1-year study period in the group showing disappearance of blood flow signals, i.e., blood flow signals within polypoidal lesions detected by optical coherence tomography angiography disappeared after the loading phase treatment (**P < 0.01). On the other hand, in the group showing persistence of blood flow signals, in which blood flow signals within polypoidal lesions persisted after the loading phase treatment, BCVA showed significant improvement at 6 months after the initial treatment (*P < 0.05), while there was no difference between the values at baseline and after 1 year.

Back to article page